BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Pharmacogenetics, Rapamycin, rs2300478, FXYD4, calcium channel activity, Leukemia)
Bookmark Forward

QuickView for MAP1LC3B;jsessionid=CCE78364B3E4D06ACF820E7DE77E8F28;jsessionid=739993EF1AC7684A1A8863A76DF15C59 (gene)


Body Atlas

Most Correlated Tissues

  1. Leukocyte (polymorphonuclear) of peripheral blood
  2. Substantia nigra pars compacta
  3. Cerebellum peduncles
  4. Basophil of peripheral blood
  5. Substantia nigra reticulata
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Injury of eye region
  2. Disorder of cornea
  3. Delayed hypersensitivity disorder
  4. Hepatocellular dysplasia
  5. Chronic fatigue syndrome
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. Ethoxyquin
  2. aleglitazar
  3. COH29
  4. Silver Nanoparticles
  5. 2-ethoxy-3-(4-((4-(methylsulfonyloxy)phenethyl)oxy)phenyl)propanoic acid
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. MIR433
  2. TBK1
  3. SETBP1
  4. PRKG1
  5. MIRLET7F1
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

Loading...
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. LC3B is lipidated to large lipid droplets during prolonged starvation for noncanonical autophagy.
  2. IGF2BP1/IMP1 Deletion Enhances a Facultative Stem Cell State via Regulation of MAP1LC3B.
  3. Dynamic changes in Beclin-1, LC3B and p62 at various time points in mice with temporary middle cereb…
  4. BNIP3-dependent mitophagy promotes cytosolic localization of LC3B and metabolic homeostasis in the l…
  5. LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation…
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

There were no clinical trials for MAP1LC3B;jsessionid=CCE78364B3E4D06ACF820E7DE77E8F28;jsessionid=739993EF1AC7684A1A8863A76DF15C59
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.